AI Insight
This study evaluated the Vivaray Hb pro, a noninvasive handheld device that measures hemoglobin levels without blood sampling, by comparing its readings against standard laboratory blood tests in 763 participants aged 8 years and older. The device showed a mean absolute error of 1.5 g/dL overall and 1.2 g/dL in the clinically important range of 8.1-13 g/dL, with a tendency to overestimate hemoglobin at lower levels and underestimate at higher levels. The study demonstrates proportional bias that varies with hemoglobin concentration, suggesting the device performs differently across the hemoglobin spectrum.
Why it matters
This technology could enable rapid, painless hemoglobin screening in clinical settings, emergency departments, and resource-limited environments where traditional blood draws are impractical or difficult. The device may be particularly useful for repeated monitoring in patients requiring frequent hemoglobin checks, such as those with anemia or undergoing chemotherapy, though the measurement error indicates it should be used as a screening tool rather than a replacement for laboratory testing.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background: Non-invasive hemoglobin measurement offers a painless and rapid alternative to conventional blood-based testing. The Vivaray Hb pro is a handheld photoplethysmography-based device designed for point-of-care hemoglobin assessment without blood sampling. We evaluated the clinical performance of the Vivaray Hb pro by comparing device-generated hemoglobin values with those obtained from a calibrated laboratory blood cell counter. Methods: In this cross-sectional, non-randomized clinical performance study, participants aged [≥]8 years were prospectively recruited. Hemoglobin was measured non-invasively using the Vivaray Hb pro and compared with venous blood samples analyzed on a calibrated Coulter counter. Agreement between methods was assessed using Bland-Altman analysis, including regression-based evaluation for proportional bias. Mean absolute error (MAE) and proportions of measurements within tolerance limits were also calculated. Complete paired measurements were available for 763 individuals. Results: Bland-Altman analysis demonstrated hemoglobin-dependent bias, with overestimation at lower hemoglobin levels and underestimation at higher levels. Regression-based analysis showed proportional bias ({beta}? = -0.178), indicating decreasing difference with increasing hemoglobin concentration. The MAE was 1.5 g/dL but was lower (1.2) in the clinically predominant ranges of 8.1-13 g/dl. Comment: The results support the use of the Vivaray Hb pro as a noninvasive hemoglobin screening and point-of-care assessment tool, particularly in settings where rapid, painless, and repeatable measurements are desirable.